The past week has been a tough one for investors in Monopar Therapeutics Inc (NASDAQ:MNPR) as the company’s stock suffered from a steady selloff and ended up with a decline of as much as 7%. In this context, it might be a good move from investors to possibly take a look at the developments from yesterday.
Market Reaction
On Thursday, MNPR stock decreased 1.13% to $2.63 with more than 1.7K shares, compared to its average volume of 14.2K shares. The stock moved within a range of $2.6100 – 2.6900 after opening trade at $2.61.
Monopar Therapeutics Reports Fourth Quarter and Full-Year 2021 Financial Results and Recent Program Developments
Monopar came into focus yesterday after it announced its financial results for the fourth fiscal quarter and the full year 2021. In addition to that, the company also provided a summer of some of the recent developments it had been working on.
Here is a quick look at some of the highlights from the financial results. The company announced that as on December 31, 2021 it had cash and cash equivalents to the tune of $20.3 million.
The company also pointed out that the current cash balance would be enough to take care of its immediate clinical trials. In the fourth quarter, the company suffered a net loss to the tune of $2.7 million and that worked out to losses of $0.21 a share. In the prior year quarter, the net losses had been $2.1 million.
Traders Review
MNPR stock is trading below the 20-Day and 50-Day Moving averages of $2.86 and $2.93 respectively. However, the stock is trading below the 200-Day moving average of $4.38.
